ABR2 Eye Drops for Dry Eye

(DRAGON Trial)

This trial aims to test the safety and ease of using new eye drops called ABR2, designed to provide temporary relief from dry eyes. In the first part, participants receive a single drop in one eye. In the second part, they use the drops up to four times a day for 28 days. This study suits individuals who frequently experience eye discomfort due to dryness and do not wear contact lenses during the trial period. As an unphased trial, participants contribute to early research and may potentially experience relief from dry eyes.

The trial protocol does not specify if you need to stop taking your current medications, but if you are using any medications that might affect the study results, the investigator may ask you to stop.

Research has shown that ABR2 eye drops are under careful study to determine their safety and ease of use. In this study, participants will use the drops to assess their effectiveness for dry eyes. Although detailed safety information about ABR2 is not yet available, it is important to note that eye drops can sometimes be recalled due to manufacturing issues. This does not imply that ABR2 has such problems, but safety remains a top priority in any eye drop study. This trial aims to evaluate the short-term safety and comfort of using ABR2, with participants closely monitored for any side effects.¹²³⁴⁵

Most treatments for dry eye, like artificial tears and anti-inflammatory medications, focus on providing temporary relief or reducing inflammation. But ABR2 eye drops take a different approach by potentially repairing the eye’s surface and improving tear production. This innovative mechanism targets the root cause of dry eye rather than just alleviating symptoms. Researchers are excited about ABR2 because it could offer longer-lasting relief and improve overall eye health, which current options struggle to achieve.

Research has shown that eye drops similar to ABR2, such as those containing rebamipide, improve how long the eye remains moist compared to regular artificial tears. They help keep the eye surface wet for longer. Other treatments for dry eye, like those with dexpanthenol, have significantly reduced symptoms such as discomfort, dryness, and redness. These treatments have also enhanced tear quality and eye moisture, which is promising for ABR2. Although ABR2 is new, the positive outcomes from similar treatments suggest it could effectively relieve dry eye symptoms. Participants in this trial will receive ABR2 eye drops to assess their effectiveness in treating dry eye symptoms.⁶⁷⁸⁹¹⁰